Study of ONO-4578 and XELOX/FOLFOX Plus Bevacizumab in Colorectal Cancer
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.
Colorectal Cancer
DRUG: ONO-4578|DRUG: ONO-4538|DRUG: Capecitabine|DRUG: Oxaliplatin|DRUG: Fluorouracil|DRUG: Calcium Levofolinate Hydrateb|DRUG: Bevacizumab
Incidence and severity of AEs and SAEs, up to 3years|Incidence and severity of clinical laboratory abnormalities, up to 3years|12-lead electrocardiography (Heart rate), up to 3years|12-lead electrocardiography (PR interval), up to 3years|12-lead electrocardiography (RR interval), up to 3years|12-lead electrocardiography (QRS width), up to 3years|12-lead electrocardiography (QT interval), up to 3years|Chest X-ray test, up to 3years|ECOG performance status, up to 3years
Objective response rate (ORR), up to 3years|Disease control rate (DCR), up to 3years|Overall survival (OS), up to 3years|Progression-free survival (PFS), up to 3years|Duration of response (DOR), up to 3years|Time to response (TTR), up to 3years|Best oveall response (BOR), up to 3years|Percentage of change in the sum of tumor diameters of target lesions, up to 3years|Maximum percent change in the sum diameters of the target lesions, up to 3years|Time course of tumor markers, up to 3years|Plasma ONO-4578 concentration, up to 3years|Serum ONO-4538 concentration, up to 3years|Anti-ONO-4538 antibody, up to 3years
To evaluate the tolerability and safety of combination of ONO-4578 and ONO-4538 and the standard of care XELOX + bevacizumab or the safety of combination of ONO-4578 and ONO-4538 and the standard of care FOLFOX + bevacizumab as first-line therapy in patients with unresectable, advanced, or recurrent colorectal cancer.